Intravitreal bevacizumab for choroidal neovascularization secondary to non-age-related macular degeneration.

Abstract

PURPOSE:

To report the long-term results of intravitreal bevacizumab (Avastin) therapy for choroidal neovascularization (CNV) secondary to non-age-related macular degeneration (non-AMD).

METHODS:

This prospective interventional case series was conducted on patients with non-AMD CNV. All patients received 1.25 mg intravitreal bevacizumab and were followed for at least 18 weeks. Indications for retreatment were decreased visual acuity or recurrence of subretinal fluid or hemorrhage associated with leakage on fluorescein angiography. Primary outcome measures were changes in best-corrected visual acuity (BCVA) and central macular thickness (CMT). Secondary outcome measures consisted of any adverse event related to the therapy.

RESULTS:

The study included 31 eyes of 28 patients with non-AMD CNV including idiopathic (n=11), due to myopia (n=7), angioid streaks (n=5), and other disorders (n=8). Mean initial BCVA was 20/100 which improved to 20/60 at 6 weeks; 20/40 at 12, 18, 24, and 36 weeks; and 20/30 at 54 weeks. Serial optical coherence tomography measurements showed mean CMT of 288 μm at baseline, which was decreased to 209 μm at last visit (P=0.95). There was no correlation between the underlying disease and changes in BCVA during the follow-up period.

CONCLUSION:

Intravitreal bevacizumab significantly improved visual acuity in eyes with non-AMD CNV due to various etiologies.

• Authors: Masoud Salehipour, Nasser Vafi, Azade Doozande, Mehdi Yaseri
• Journal: Journal of ophthalmic & vision research (J Ophthalmic Vis Res) Vol. 5 Issue 1 Pg. 10-9 (Jan 2010) ISSN: 2008-2010 [Print] United Arab Emirates
• PMID: 22737321 (Publication Type: Journal Article)